Cision Newshttps://news.cision.comCision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.Tue, 09 Jun 2026 15:04:53 GMTCision News14660https://news.cision.comhttps://news.cision.com/Content/img/news-logo.pngMedivir comments on the patent approvalhttps://news.cision.com/medivir/r/medivir-comments-on-the-patent-approval,c4121620cision5011306Thu, 20 Mar 2025 07:41:30 GMTMedivir’s CEO to BioStock: “I am proud to see our research contribute to a global solution”https://news.cision.com/medivir/r/medivir-s-ceo-to-biostock---i-am-proud-to-see-our-research-contribute-to-a-global-solution-,c4115729cision5003059Fri, 07 Mar 2025 07:40:24 GMTBioStock: Medivir’s investigator on the positive results directly from EASLhttps://news.cision.com/medivir/r/biostock-medivir-s-investigator-on-the-positive-results-directly-from-easl,c4109440cision4994240Fri, 21 Feb 2025 09:38:26 GMTMedivir’s CEO: “We have attracted interest from the best investigators and hospitals to be part of the phase IIb study”https://news.cision.com/medivir/r/medivir-s-ceo---we-have-attracted-interest-from-the-best-investigators-and-hospitals-to-be-part-of-t,c4107497cision4991560Tue, 18 Feb 2025 13:05:29 GMTBioStock: Medivir to highlight promising clinical data at EASLhttps://news.cision.com/medivir/r/biostock-medivir-to-highlight-promising-clinical-data-at-easl,c4086254cision4962843Mon, 23 Dec 2024 12:05:55 GMTMedivir’s CEO to BioStock: “The IND approval is a very important milestone”https://news.cision.com/medivir/r/medivir-s-ceo-to-biostock---the-ind-approval-is-a-very-important-milestone-,c4082631cision4958066Mon, 16 Dec 2024 10:07:18 GMTBioStock: Medivir’s phase Ib/IIa study successfully concludedhttps://news.cision.com/medivir/r/biostock-medivir-s-phase-ib-iia-study-successfully-concluded,c4073656cision4948555Fri, 29 Nov 2024 11:34:29 GMTMedivir’s CEO: “There is an obvious need for fostrox”https://news.cision.com/medivir/r/medivir-s-ceo---there-is-an-obvious-need-for-fostrox-,c4064055cision4935565Mon, 11 Nov 2024 08:55:29 GMTBioStock: Medivir signs new clinical trial collaboration with Eisaihttps://news.cision.com/medivir/r/biostock-medivir-signs-new-clinical-trial-collaboration-with-eisai,c4061029cision4931475Mon, 04 Nov 2024 15:41:24 GMTMedivir will present at the BioStock Life Science Summit, November 20https://news.cision.com/medivir/r/medivir-will-present-at-the-biostock-life-science-summit--november-20,c4059498cision4931111Mon, 04 Nov 2024 10:00:00 GMTMedivir's CEO to BioStock: "Fostrox is unique in its kind"https://news.cision.com/medivir/r/medivir-s-ceo-to-biostock---fostrox-is-unique-in-its-kind-,c4056706cision4925894Fri, 25 Oct 2024 14:13:50 GMTMedivir to present at the Pareto Securities Healthcare Conferencehttps://news.cision.com/medivir/r/medivir-to-present-at-the-pareto-securities-healthcare-conference,c4039274cision4901807Wed, 18 Sep 2024 11:16:11 GMTBioStock: Medivir – live from ESMO in Barcelonahttps://news.cision.com/medivir/r/biostock--medivir---live-from-esmo-in-barcelona,c4038223cision4901122Tue, 17 Sep 2024 13:45:03 GMTMedivir’s fostrox + Lenvima confirm promise of improved outcomes in advanced liver cancer, detailed and mature data presented at ESMOhttps://news.cision.com/medivir/r/medivir-s-fostrox---lenvima-confirm-promise-of-improved-outcomes-in-advanced-liver-cancer--detailed-,c4037691cision4899736Mon, 16 Sep 2024 07:00:00 GMTMedivir to present mature clinical data for fostrox + Lenvima at ESMO Conference and to host a webcast on September 16https://news.cision.com/medivir/r/medivir-to-present-mature-clinical-data-for-fostrox---lenvima-at-esmo-conference-and-to-host-a-webca,c4036638cision4898447Thu, 12 Sep 2024 11:05:00 GMTBioStock: Q2 marked continued progress for Medivir in advanced liver cancerhttps://news.cision.com/medivir/r/biostock-q2-marked-continued-progress-for-medivir-in-advanced-liver-cancer,c4028416cision4886966Mon, 26 Aug 2024 07:50:49 GMTMEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2024https://news.cision.com/medivir/r/medivir-ab---interim-report-january---june-2024,c4027140cision4885267Thu, 22 Aug 2024 06:30:00 GMTMedivir to present updated clinical data for fostrox + Lenvima in HCC at ESMO Conference in Septemberhttps://news.cision.com/medivir/r/medivir-to-present-updated-clinical-data-for-fostrox---lenvima-in-hcc-at-esmo-conference-in-septembe,c4016114cision4870603Thu, 18 Jul 2024 06:30:00 GMTNumber of shares and votes in Medivir AB on 28 June 2024https://news.cision.com/medivir/r/number-of-shares-and-votes-in-medivir-ab-on-28-june-2024,c4008524cision4859785Fri, 28 Jun 2024 08:45:00 GMTBioStock: Medivir presents promising results in difficult-to-treat patient populationhttps://news.cision.com/medivir/r/biostock-medivir-presents-promising-results-in-difficult-to-treat-patient-population,c4007314cision4858802Thu, 27 Jun 2024 08:00:00 GMTFostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GIhttps://news.cision.com/medivir/r/fostrox---lenvima--holds-promise-of-greatly-improved-outcomes-for-advanced-liver-cancer-patients--re,c4007515cision4858673Thu, 27 Jun 2024 07:00:00 GMTMedivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibilityhttps://news.cision.com/medivir/r/medivir-selects-global-cro-partner-for-upcoming-phase-2b-study-in-hcc-with-fostrox---lenvima-and-ini,c4003647cision4853111Wed, 19 Jun 2024 08:20:00 GMTIssue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024https://news.cision.com/medivir/r/issue--repurchase-and-reclassification-of-shares-of-series-c-and-transfer-of-ordinary-shares-under-l,c3991919cision4836614Thu, 30 May 2024 10:20:00 GMTMedivir to present at Redeye Growth Dayhttps://news.cision.com/medivir/r/medivir-to-present-at-redeye-growth-day,c3991569cision4836367Thu, 30 May 2024 07:05:00 GMT